Fig. 3: Early ICI prolongs overall survival following RPT + ICI in the immune resistant B78 melanoma model. | Nature Communications

Fig. 3: Early ICI prolongs overall survival following RPT + ICI in the immune resistant B78 melanoma model.

From: Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice

Fig. 3: Early ICI prolongs overall survival following RPT + ICI in the immune resistant B78 melanoma model.The alternative text for this image may have been generated using AI.

A Treatment regimen options for in vivo therapy studies. Mice either received early (days −3/0/3), intermediate (days 4/7/10), or delayed (days 11/14/17) dual anti-CTLA4 and anti-PD-L1 relative to RPT on day 1. B–I B78 tumor-bearing mice were randomized to one of 14 treatment groups: untreated control (No Tx), dual anti-CTLA4 and anti-PD-L1 (ICI) on days 4/7/10, or 2 Gy 90Y-NM600 (0.7326 MBq), 177Lu-NM600 (1.702 MBq), or 225Ac-NM600 (18.5 kBq) on day 1, or combination 2 Gy 90Y-, 177Lu-, 225Ac-NM600 on day 1 with dual ICI on days −3/0/3 (90Y/177Lu only), days 4/7/10, or days 11/14/17, or 225Ac-NM600 + ICI on days −8/−5/−2. B–E Individual tumor growth curves corresponding to (F, G). F, H Effects of varied ICI timing for each radionuclide on tumor growth and overall survival. G, I Effects of varied radionuclide for each ICI timing of combination therapy on tumor growth and overall survival. B–I Results of one experiment. B–I N = 9: 90Y-, 177Lu-, 225Ac-NM600 + ICI 4/7/10 or + ICI 11/14/17; n = 7: 90Y-, 177Lu-, 225Ac-NM600 + ICI −3/0/3; n = 5: 90Y-, 177Lu-, 225Ac-NM600, ICI 4/7/10, No Tx. Linear mixed models were used to compare tumor volumes over time between various treatment groups. Statistical testing of the pairwise contrasts was adjusted for multiple comparisons using Tukey’s method. Log-rank test was used to compare survival. Error bars are SEM.

Back to article page